Therapeutic approaches to the regulation of metabolism of high-density lipoprotein: Novel HDL-directed pharmacological intervention and exercise

Circulation Journal

Volumn 77, Issue 11, 2013, Pages 2651-2663

  Zhang, Bo ^a   Kawachi, Emi ^a   Miura, Shin Ichiro ^a   Uehara, Yoshinari ^a   Matsunaga, Akira ^a   Kuroki, Masahide ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cholesteryl ester transfer protein; Coronary artery disease; Exercise training; High density lipoprotein; Lifestyle change

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; CSL 112; DALCETRAPIB; ETC 216; EVACETRAPIB; FIBRIC ACID DERIVATIVE; FUKUOKA UNIVERSITY APOLIPOPROTEIN A1 MIMETIC PEPTIDE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEPTIDOMIMETIC AGENT; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; EXERCISE; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; REVIEW; SMOKING CESSATION;

APOLIPOPROTEIN A-I; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; EXERCISE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X;

EID: 84886502812     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1584     Document Type: Review

References (157)

1. Zhang B, Miura S, Yanagi D, Noda K, Nishikawa H, Matsunaga A, et al. Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: The SPECIAL Study. Atherosclerosis 2008; 201: 353-359
2. Zhang B, Matsunaga A, Rainwater DL, Miura S, Noda K, Nishikawa H, et al. Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: The ROSARY Study. J Lipid Res 2009; 50: 1832-1841
3. Saku K, Zhang B, Noda K. Randomized head-to-head comparison lipoof pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): The PATROL trial. Circ J 2011; 75: 1493-1505
4. Zhang B, Kawachi E, Matsunaga A, Imaizumi S, Noda K, Uehara Y, et al. Reactivity of direct assays for low-density lipoprotein (LDL) cholesterol toward charge-modified LDL in hypercholesterolemia. Circ J 2012; 76: 2241-2248
5. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590
6. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Metaanalysis of statin effects in women versus men. J Am Coll Cardiol 2012; 59: 572-582
7. Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr Opin Cardiol 2006; 21: 400-404
8. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-732
9. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310
10. Manolio TA. Cohort studies and the genetics of complex disease. Nat Genet 2009; 41: 5-6
11. Kontush A, Chapman MJ. High-density lipoproteins: Structure, metabolsim, function, and therapeutics. New Jersey: John Wiley & Sons, 2012
12. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study. Lancet 2012; 380: 572-580
13. Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: A Mendelian randomization study of HDL cholesterol in 54, 500 individuals. J Clin Endocrinol Metab 2012; 97: E248-E256
14. von Eckardstein A, Sibler RA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011; 22: 26-32
15. Ahmad T, Chasman DI, Buring JE, Lee IM, Ridker PM, Everett BM. Physical activity modifies the effect of LPL, LIPC, and CETP polymorphisms on HDL-C levels and the risk of myocardial infarction in women of European ancestry. Circ Cardiovasc Genet 2011; 4: 74-80
16. Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb 2010; 17: 436-451
17. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504
18. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435
19. Duffy D, Rader DJ. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006; 113: 1140-1150
20. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-2415
21. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099
22. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012; 223: 1-68
23. Ton VK, Martin SS, Blumenthal RS, Blaha MJ. Comparing the new European cardiovascular disease prevention guideline with prior American Heart Association guidelines: An editorial review. Clin Cardiol 2013; 36: E1-E6, doi:10.1002/clc.22079
24. Kiens B, Lithell H. Lipoprotein metabolism influenced by traininginduced changes in human skeletal muscle. J Clin Invest 1989; 83: 558-564
25. Shiroma EJ, Lee IM. Physical activity and cardiovascular health: Lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation 2010; 122: 743-752
26. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29: 431-438
27. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 2012; 125: 1905-1919
28. Murphy AJ, Bijl N, Yvan-Charvet L, Welch CB, Bhagwat N, Reheman A, et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med 2013; 19: 586-594
29. Schulman IG. Nuclear receptors as drug targets for metabolic disease. Adv Drug Deliv Rev 2010; 62: 1307-1315
30. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006; 116: 607-614
31. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211-228
32. Rye KA, Barter PJ. Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochim Biophys Acta 2012; 1821: 473-480
33. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010; 21: 229-238
34. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. J Lipid Res 2009; 50(Suppl): S195-S200
35. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984; 25: 1017-1058
36. Tall AR. Plasma high density lipoproteins: Metabolism and relationship to atherogenesis. J Clin Invest 1990; 86: 379-384
37. Lee JY, Lanningham-Foster L, Boudyguina EY, Smith TL, Young ER, Colvin PL, et al. Prebeta high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice. J Lipid Res 2004; 45: 716-728
38. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005; 115: 1333-1342
39. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 2001; 155: 269-281
40. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, Rader DJ. Characterization of the lipolytic activity of endothelial lipase. J Lipid Res 2002; 43: 921-929
41. Jaye M, Krawiec J. Endothelial lipase and HDL metabolism. Curr Opin Lipidol 2004; 15: 183-189
42. Jahangiri A, Rader DJ, Marchadier D, Curtiss LK, Bonnet DJ, Rye KA. Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res 2005; 46: 896-903
43. Webb NR, Cai L, Ziemba KS, Yu J, Kindy MS, van der Westhuyzen DR, et al. The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake. J Lipid Res 2002; 43: 1890-1898
44. de Beer MC, Webb NR, Whitaker NL, Wroblewski JM, Jahangiri A, van der Westhuyzen DR, et al. SR-BI selective lipid uptake: Subsequent metabolism of acute phase HDL. Arterioscler Thromb Vasc Biol 2009; 29: 1298-1303
45. Harder CJ, McPherson R. HDL remodeling by CETP and SR-BI. In: Fielding CJ, editor. High-density lipoproteins: From basic biology to clinical aspects. WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Federal Republic of Germany, 2007; 163-182
46. Gauthier A, Lau P, Zha X, Milne R, McPherson R. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 2005; 25: 2177-2184
47. Cavelier C, Ohnsorg PM, Rohrer L, von Eckardstein A. The betachain of cell surface F(0)F(1) ATPase modulates apoA-I and HDL transcytosis through aortic endothelial cells. Arterioscler Thromb Vasc Biol 2012; 32: 131-139
48. Rohrer L, Ohnsorg PM, Lehner M, Landolt F, Rinninger F, von Eckardstein A. High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. Circ Res 2009; 104: 1142-1150
49. Cavelier C, Rohrer L, von Eckardstein A. ATP-Binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells. Circ Res 2006; 99: 1060-1066
50. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008; 263: 256-273
51. Hansson GK, Bjorkholm M. Medicine. Tackling two diseases with HDL. Science 2010; 328: 1641-1642
52. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010; 30: 139-143
53. Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012; 8: 237-245
54. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-772
55. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985; 39: 1-8
56. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127-135
57. Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ. The antioxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 2011; 58: 2068-2075
58. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 2012; 60: 2372-2379
59. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-2756
60. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-2767
61. Heinecke J. HDL and cardiovascular-disease risk: Time for a new approach? N Engl J Med 2011; 364: 170-171
62. Hoofnagle AN, Wu M, Gosmanova AK, Becker JO, Wijsman EM, Brunzell JD, et al. Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arterioscler Thromb Vasc Biol 2010; 30: 2528-2534
63. Wiesner P, Leidl K, Boettcher A, Schmitz G, Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009; 50: 574-585
64. Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 2011; 121: 1402-1411
65. Marsche G, Furtmuller PG, Obinger C, Sattler W, Malle E. Hypochlorite- modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro. Cardiovasc Res 2008; 79: 187-194
66. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase- catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529-541
67. Hadfield KA, Pattison DI, Brown BE, Hou L, Rye KA, Davies MJ, et al. Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional HDL: Comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl). Biochem J 2013; 449: 531-542
68. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012; 32: 2813-2820
69. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011; 8: 222-232
70. Iacob AO, Choudhury RP. Targeting HDL-cholesterol to reduce residual cardiovascular risk. Curr Opin Lipidol 2012; 23: 172-174
71. Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010; 210: 35-40
72. Barter PJ, Rye KA. Cardioprotective properties of fibrates: Which fibrate, which patients, what mechanism? Circulation 2006; 113: 1553-1555
73. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985; 75: 1702-1712
74. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093
75. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010; 126: 314-345
76. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007; 99: 22C-31C.
77. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: A systematic review and meta-regression. J Am Coll Cardiol 2013; 61: 440-446
78. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008; 101: 20B-26B.
79. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, et al. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 1993; 92: 1650-1658
80. Cuchel M, Rader DJ. Genetics of increased HDL cholesterol levels: Insights into the relationship between HDL metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 1710-1712
81. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-1316
82. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620-1630
83. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial. Lancet 2007; 370: 153-160
84. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122
85. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial. Lancet 2011; 378: 1547-1559
86. Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: The dal-VESSEL randomized clinical trial. Eur Heart J 2012; 33: 857-865
87. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW 3rd, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009; 157: 352-360. e2
88. Cao G, Beyer TP, Zhang Y, Schmidt RJ, Chen YQ, Cockerham SL, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 2011; 52: 2169-2176
89. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial. JAMA 2011; 306: 2099-2109
90. Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: A pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008; 118: 2515-2522
91. Connelly MA, Parry TJ, Giardino EC, Huang Z, Cheung WM, Chen C, et al. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. J Cardiovasc Pharmacol 2010; 55: 459-468
92. Simic B, Hermann M, Shaw SG, Bigler L, Stalder U, Dorries C, et al. Torcetrapib impairs endothelial function in hypertension. Eur Heart J 2012; 33: 1615-1624
93. Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010; 51: 3443-3454
94. Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag 2012; 8: 323-331
95. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, et al. Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158: 896-901. e3
96. REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease. http://clinicaltrials.gov/show/ NCT01252953 (accessed November 29, 2012).
97. A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE). Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes. http://clinicaltrials.gov/show/ NCT01687998 (accessed June 7, 2013).
98. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290: 2292-2300
99. Angelin B, Parini P, Eriksson M. Reverse cholesterol transport in man: Promotion of fecal steroid excretion by infusion of reconstituted HDL. Atheroscler Suppl 2002; 3: 23-30
100. Diditchenko S, Gille A, Pragst I, Stadler D, Waelchli M, Hamilton R, et al. Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux. Arterioscler Thromb Vasc Biol 2013; 33: 2202-2211
101. Uehara Y, Ando S, Yahiro E, Oniki K, Ayaori M, Abe S, et al. FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in apoEdeficient mice. J Am Heart Assoc 2013; 2: e000048
102. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, et al. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ J 2011; 75: 1533-1538
103. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: A systematic review. JAMA 2007; 298: 786-798
104. Pownall HJ, Ballantyne CM, Kimball KT, Simpson SL, Yeshurun D, Gotto AM Jr. Effect of moderate alcohol consumption on hypertriglyceridemia: A study in the fasting state. Arch Intern Med 1999; 159: 981-987
105. Asztalos B, Lefevre M, Wong L, Foster TA, Tulley R, Windhauser M, et al. Differential response to low-fat diet between low and normal HDL-cholesterol subjects. J Lipid Res 2000; 41: 321-328
106. Knopp RH, Walden CE, Retzlaff BM, McCann BS, Dowdy AA, Albers JJ, et al. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men: The Dietary Alternatives Study. JAMA 1997; 278: 1509-1515
107. Durstine JL, Grandjean PW, Davis PG, Ferguson MA, Alderson NL, DuBose KD. Blood lipid and lipoprotein adaptations to exercise: A quantitative analysis. Sports Med 2001; 31: 1033-1062
108. Tseng ML, Ho CC, Chen SC, Huang YC, Lai CH, Liaw YP. A simple method for increasing levels of high-density lipoprotein cholesterol: a pilot study of combination aerobic- and resistanceexercise training. Int J Sport Nutr Exerc Metab 2013; 23: 271-281
109. Hayashino Y, Jackson JL, Fukumori N, Nakamura F, Fukuhara S. Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2012; 98: 349-360
110. Kodama S, Tanaka S, Saito K, Shu M, Sone Y, Onitake F, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: A meta-analysis. Arch Intern Med 2007; 167: 999-1008
111. Kelley GA, Kelley KS, Franklin B. Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: A meta-analysis of randomized controlled trials. J Cardiopulm Rehabil 2006; 26: 131-134
112. Leon AS, Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc 2001; 33: S502-S515, discussion S528-S509
113. Thompson PD, Cullinane EM, Sady SP, Flynn MM, Bernier DN, Kantor MA, et al. Modest changes in high-density lipoprotein concentration and metabolism with prolonged exercise training. Circulation 1988; 78: 25-34
114. Crouse SF, O'Brien BC, Grandjean PW, Lowe RC, Rohack JJ, Green JS. Effects of training and a single session of exercise on lipids and apolipoproteins in hypercholesterolemic men. J Appl Physiol 1997; 83: 2019-2028
115. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347: 1483-1492
116. Durstine JL, Grandjean PW, Cox CA, Thompson PD. Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil 2002; 22: 385-398
117. Kelley GA, Kelley KS. Aerobic exercise and HDL2-C: A meta analysis of randomized controlled trials. Atherosclerosis 2006; 184: 207-215
118. Thompson PD, Yurgalevitch SM, Flynn MM, Zmuda JM, Spannaus- Martin D, Saritelli A, et al. Effect of prolonged exercise training without weight loss on high-density lipoprotein metabolism in overweight men. Metabolism 1997; 46: 217-223
119. Casella-Filho A, Chagas AC, Maranhao RC, Trombetta IC, Cesena FH, Silva VM, et al. Effect of exercise training on plasma levels and functional properties of high-density lipoprotein cholesterol in the metabolic syndrome. Am J Cardiol 2011; 107: 1168-1172
120. Szostak J, Laurant P. The forgotten face of regular physical exercise: A 'natural' anti-atherogenic activity. Clin Sci (Lond) 2011; 121: 91-106
121. Joyner MJ, Green DJ. Exercise protects the cardiovascular system: Effects beyond traditional risk factors. J Physiol 2009; 587: 5551-5558
122. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: Mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 2011; 11: 607-615
123. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: Skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012; 8: 457-465
124. Brandt C, Pedersen BK. The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. J Biomed Biotechnol 2010; 2010: 520258
125. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: Focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379-1406
126. Nielsen S, Pedersen BK. Skeletal muscle as an immunogenic organ. Curr Opin Pharmacol 2008; 8: 346-351
127. Greene NP, Fluckey JD, Lambert BS, Greene ES, Riechman SE, Crouse SF. Regulators of blood lipids and lipoproteins? PPARdelta and AMPK, induced by exercise, are correlated with lipids and lipoproteins in overweight/obese men and women. Am J Physiol Endocrinol Metab 2012; 303: E1212-E1221
128. Couillard C, Despres JP, Lamarche B, Bergeron J, Gagnon J, Leon AS, et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: Evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001; 21: 1226-1232
129. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008; 54: 788-800
130. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011; 17: 594-603
131. Irving BA, Davis CK, Brock DW, Weltman JY, Swift D, Barrett EJ, et al. Effect of exercise training intensity on abdominal visceral fat and body composition. Med Sci Sports Exerc 2008; 40: 1863-1872
132. Katzmarzyk PT, Leon AS, Rankinen T, Gagnon J, Skinner JS, Wilmore JH, et al. Changes in blood lipids consequent to aerobic exercise training related to changes in body fatness and aerobic fitness. Metabolism 2001; 50: 841-848
133. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: Mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 2011; 11: 607-615
134. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97
135. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975-981
136. Belalcazar LM, Lang W, Haffner SM, Hoogeveen RC, Pi-Sunyer FX, Schwenke DC, et al. Adiponectin and the mediation of HDLcholesterol change with improved lifestyle: The Look AHEAD Study. J Lipid Res 2012; 53: 2726-2733
137. Kriketos AD, Gan SK, Poynten AM, Furler SM, Chisholm DJ, Campbell LV. Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care 2004; 27: 629-630
138. Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, et al. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 2006; 26: 1364-1369
139. Matsuura F, Oku H, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007; 358: 1091-1095
140. Oku H, Matsuura F, Koseki M, Sandoval JC, Yuasa-Kawase M, Tsubakio-Yamamoto K, et al. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett 2007; 581: 5029-5033
141. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F, et al. AMPK and SIRT1: A long-standing partnership? Am J Physiol Endocrinol Metab 2010; 298: E751-E760
142. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 2007; 104: 12017-12022
143. Haigis MC, Guarente LP. Mammalian sirtuins: Emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20: 2913-2921
144. Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009; 20: 98-105
145. Dominy JE Jr, Lee Y, Gerhart-Hines Z, Puigserver P. Nutrientdependent regulation of PGC-1alpha's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5. Biochim Biophys Acta 2010; 1804: 1676-1683
146. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458: 1056-1060
147. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, et al. AMPK activity is diminished in tissues of IL-6 knockout mice: The effect of exercise. Biochem Biophys Res Commun 2004; 320: 449-454
148. Richter EA, Ruderman NB. AMPK and the biochemistry of exercise: Implications for human health and disease. Biochem J 2009; 418: 261-275
149. Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, Xiang X, et al. Interleukin-6 regulation of AMP-activated protein kinase: Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 2006; 55(Suppl 2): S48-S54
150. Suwa M, Nakano H, Radak Z, Kumagai S. Endurance exercise increases the SIRT1 and peroxisome proliferator-activated receptor gamma coactivator-1alpha protein expressions in rat skeletal muscle. Metabolism 2008; 57: 986-998
151. Fulco M, Sartorelli V. Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle 2008; 7: 3669-3679
152. Lomb DJ, Laurent G, Haigis MC. Sirtuins regulate key aspects of lipid metabolism. Biochim Biophys Acta 2010; 1804: 1652-1657
153. Burri L, Thoresen GH, Berge RK. The role of PPARalpha activation in liver and muscle. PPAR Res 2010; 2010: Article ID 542359,11 pages.
154. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007; 28: 91-106
155. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca2+ and AMPK/SIRT1. Nature 2010; 464: 1313-1319
156. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: Mechanisms for activation and possible biological roles. FASEB J 2002; 16: 1335-1347
157. Kelly M, Gauthier MS, Saha AK, Ruderman NB. Activation of AMPactivated protein kinase by interleukin-6 in rat skeletal muscle: Association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes 2009; 58: 1953-1960.